Baseline plasma fibrinogen is associated with haemoglobin A1c and 2-year major adverse cardiovascular events following percutaneous coronary intervention in patients with acute coronary syndrome: a single-centre, prospective cohort study
- PMID: 31014348
- PMCID: PMC6480802
- DOI: 10.1186/s12933-019-0858-5
Baseline plasma fibrinogen is associated with haemoglobin A1c and 2-year major adverse cardiovascular events following percutaneous coronary intervention in patients with acute coronary syndrome: a single-centre, prospective cohort study
Abstract
Background: Despite revascularisation, a large proportion of acute coronary syndrome (ACS) patients continue to experience major adverse cardiovascular events (MACEs), which are worsened by diabetes mellitus (DM). Fibrinogen (FIB) is a risk factor for MACEs in coronary artery disease and often elevated in DM. However, the relationships between FIB, glucose metabolism (haemoglobin A1c [HbA1c] and fasting blood glucose [FBG]) and MACEs following percutaneous coronary intervention (PCI) in DM, non-DM or whole patients with ACS remains unknown.
Methods: A total of 411 ACS patients undergoing PCI were enrolled in this study. We compared baseline FIB levels between DM (n = 103) and non-DM (n = 308) patients and divided participants into three groups according to FIB level, i.e. FIB-L, FIB-M and FIB-H, to compare baseline characteristics and MACEs. Linear regression analysis of the relationship between glucose metabolism and FIB, Cox regression, survival and landmark analyses of MACEs were also performed over a median of 27.55 months of follow-up.
Results: Patients with DM had higher FIB levels than non-DM patients (3.56 ± 0.99 mg/dL vs. 3.34 ± 0.80 mg/dL, P < 0.05). HbA1c and FBG were significantly positively correlated with FIB in whole and DM patients but not in non-DM patients (all P < 0.05). Compared with the FIB-L group, the FIB-M (hazard ratio [HR] 1.797, 95% CI 1.117-2.892, P = 0.016) and FIB-H (HR 1.664, 95% CI 1.002-2.763, P = 0.049) groups were associated with higher MACEs in whole; the FIB-M (HR 7.783, 95% CI 1.012-59.854, P = 0.049) was associated with higher MACEs in DM patients. FIB was not associated with MACEs in non-DM patients. During landmark analysis, FIB showed better predictive value for MACEs after PCI in the first 30 months of follow up than in the subsequent period.
Conclusion: In this study from China, FIB was positively associated with glucose metabolism (HbA1c and FBG) in whole and DM populations with ACS. Moreover, elevated baseline FIB levels may be an important and independent predictor of MACEs following PCI, especially amongst those with DM. However, as the follow-up period increased, the baseline FIB levels lost their ability to predict MACEs.
Keywords: Acute coronary syndromes; Diabetes mellitus; Fasting blood glucose; Fibrinogen; HbA1c; Major adverse cardiovascular events; Percutaneous coronary intervention.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures



Similar articles
-
Fibrinogen is associated with glucose metabolism and cardiovascular outcomes in patients with coronary artery disease.Cardiovasc Diabetol. 2020 Mar 19;19(1):36. doi: 10.1186/s12933-020-01012-9. Cardiovasc Diabetol. 2020. PMID: 32192491 Free PMC article.
-
Prognostic value of fibrinogen in patients with coronary artery disease and prediabetes or diabetes following percutaneous coronary intervention: 5-year findings from a large cohort study.Cardiovasc Diabetol. 2021 Jul 16;20(1):143. doi: 10.1186/s12933-021-01335-1. Cardiovasc Diabetol. 2021. PMID: 34271936 Free PMC article.
-
Adjustment of the GRACE score by HemoglobinA1c enables a more accurate prediction of long-term major adverse cardiac events in acute coronary syndrome without diabetes undergoing percutaneous coronary intervention.Cardiovasc Diabetol. 2015 Aug 19;14:110. doi: 10.1186/s12933-015-0274-4. Cardiovasc Diabetol. 2015. PMID: 26285575 Free PMC article.
-
Long-term prognosis of chronic total occlusion treated by successful percutaneous coronary intervention in patients with or without diabetes mellitus: a systematic review and meta-analysis.Cardiovasc Diabetol. 2021 Jan 30;20(1):29. doi: 10.1186/s12933-021-01223-8. Cardiovasc Diabetol. 2021. PMID: 33516214 Free PMC article.
-
Prognostic value of HbA1c for in-hospital and short-term mortality in patients with acute coronary syndrome: a systematic review and meta-analysis.Cardiovasc Diabetol. 2019 Dec 11;18(1):169. doi: 10.1186/s12933-019-0970-6. Cardiovasc Diabetol. 2019. PMID: 31829179 Free PMC article.
Cited by
-
The association between fibrinogen levels and severity of coronary artery disease and long-term prognosis following percutaneous coronary intervention in patients with type 2 diabetes mellitus.Front Endocrinol (Lausanne). 2023 Nov 29;14:1287855. doi: 10.3389/fendo.2023.1287855. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 38093962 Free PMC article.
-
A Novel Biomarker Scoring System Alone or in Combination with the GRACE Score for the Prognostic Assessment in Non-ST-Elevation Myocardial Infarction.Clin Epidemiol. 2022 Aug 2;14:911-923. doi: 10.2147/CLEP.S370004. eCollection 2022. Clin Epidemiol. 2022. PMID: 35942185 Free PMC article.
-
Correlation between admission blood glucose, fibrinogen, and slow blood flow during primary PCI for acute ST segment elevation myocardial infarction.Front Cardiovasc Med. 2024 Dec 3;11:1478743. doi: 10.3389/fcvm.2024.1478743. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 39691498 Free PMC article.
-
Predictive impact of fibrinogen-to-albumin ratio (FAR) for left ventricular dysfunction in acute coronary syndrome: a cross-sectional study.Eur J Med Res. 2023 Feb 8;28(1):68. doi: 10.1186/s40001-023-01029-2. Eur J Med Res. 2023. PMID: 36755341 Free PMC article.
-
Day-to-day fasting plasma glucose variability on the short-term prognosis of ST-segment elevation myocardial infarction: A retrospective cohort study.Clin Cardiol. 2022 Dec;45(12):1246-1254. doi: 10.1002/clc.23899. Epub 2022 Sep 7. Clin Cardiol. 2022. PMID: 36069119 Free PMC article.
References
-
- Murray CJ, Barber RM, Foreman KJ, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet. 2015;386(10009):2145–2191. doi: 10.1016/S0140-6736(15)61340-X. - DOI - PMC - PubMed
-
- Navarese EP, De Luca G, Castriota F, et al. Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis. J Thromb Haemost. 2011;9(10):1902–1915. doi: 10.1111/j.1538-7836.2011.04445.x. - DOI - PubMed
-
- De Luca G, Verdoia M, Suryapranata H. Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials. Atherosclerosis. 2012;222(2):426–433. doi: 10.1016/j.atherosclerosis.2012.02.041. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous